Literature DB >> 14237786

MALIGNANT MELANOMA OF CHOROID. REPORT OF A CASE WITH CLINICAL HISTORY OF 36 YEARS AND FOLLOW UP OF 32 YEARS.

F H NEWTON.   

Abstract

Entities:  

Keywords:  CHOROID NEOPLASMS; LIVER NEOPLASMS; MELANOMA; NEOPLASM METASTASIS; PATHOLOGY; PROGNOSIS; SURGERY, OPERATIVE

Mesh：

Year:  1965        PMID： 14237786     DOI： 10.1001/archopht.1965.00970030200009

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  7 in total

Review 1.  Management of intraocular melanoma.

Authors:  W S Foulds
Journal:  Br J Ophthalmol       Date:  1990-09       Impact factor: 4.638

2.  Lymphoproliferative response as an index of cellular immunity in malignant melanoma of the uvea and its correlation with the histological features of the tumour.

Authors:  M S Sunba; A H Rahi; G Morgan; E J Holborow
Journal:  Br J Ophthalmol       Date:  1980-08       Impact factor: 4.638

3.  Autoimmune reactions in uveal melanoma.

Authors:  A H Rahi
Journal:  Br J Ophthalmol       Date:  1971-12       Impact factor: 4.638

4.  HLA expression and tumor-infiltrating immune cells in uveal melanoma.

Authors:  I de Waard-Siebinga; C G Hilders; B E Hansen; J L van Delft; M J Jager
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-01       Impact factor: 3.117

5.  Prognostic factors following enucleation of 111 uveal melanomas.

Authors:  K Coleman; J P Baak; P Van Diest; J Mullaney; M Farrell; M Fenton
Journal:  Br J Ophthalmol       Date:  1993-11       Impact factor: 4.638

6.  Identification of monosomy 3 in choroidal melanoma by chromosome in situ hybridisation.

Authors:  M T Sandinha; M A Farquharson; F Roberts
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

7.  Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients.

Authors:  J Kan-Mitchell; P E Liggett; W Harel; L Steinman; T Nitta; J R Oksenberg; M R Posner; M S Mitchell
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.